Rhodes A, Eastwood JB, Smith SA. Early acute hepatitis with parental amiodarone: a toxic effect of the vehicle[J]. Gut, 1993, 34: 565-566.
[3]
Hirama S, Tatsuishi T, 1wase K, et al. Flow-cytometric analysis on adverse effects of polysorbate 80 in rat thymocytes[J]. Toxicology, 2004, 199(2-3): 137-143.
[4]
Anja Z, Karin B, Rejane M. The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells[J]. Biochem Pharmacol, 2011, 81(3): 432-441.
[5]
Tisdale JE, Follin SL, Ordelova A, et al. Risk factors for the development of specific noncardiovascular adverse effects associated with amiodarone[J]. J Clin Phamacol, 1995, 35(4): 351-356.
[6]
Mattar W, Juliar B, Gradus-Pizlo I, et al. Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure[J]. Gastrointestin Liver Dis, 2009, 18(4): 419-423.
[7]
Kum LC, Chan WW, Hui HH, et al. Prevalence of amiodarone-related hepatotoxicity in 720 Chinese patients with or without baseline liver dysfunction[J]. Clin Cardiol, 2006, 29(7): 295-299.
Mountfield RJ, Senepin S, Schleimer M, et al. Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450[J]. Int J Pharm, 2000, 211(1-2): 89-92.
Emanuela R, Elena I, Roberto M, et al. Acute toxic hepatitis after amiodarone intravenous loading[J]. Am J Emerg Med, 2007, 25: 1082e1-1082e4.
[13]
Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications[J]. JAMA. 2007, 298(11): 1312-1322.
[14]
Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007[J]. Heart Rhythm, 2007, 4(9): 1250-1259.
